Namuscla 167 mg hard capsules, Mexiletine granules for prolonged-release oral suspension 167 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg
MEX-NDM-301
Phase 3 small_molecule active
Quick answer
Namuscla 167 mg hard capsules, Mexiletine granules for prolonged-release oral suspension 167 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg for Non-Dystrophic Myotonias (NDM) is a Phase 3 program (small_molecule) at Lupin Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lupin Europe GmbH
- Indication
- Non-Dystrophic Myotonias (NDM)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active